Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02243371 · ClinicalTrials.gov registry record · Phase 2
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
A Phase 2 study of Previously Treated Metastatic Adenocarcinoma of the Pancreas, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
- 5
- Study locations
NCT02243371: Completed Phase 2 study of Previously Treated Metastatic Adenocarcinoma of the Pancreas, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT02243371 is a Phase 2 study of Previously Treated Metastatic Adenocarcinoma of the Pancreas that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02243371, a Phase 2 study of Previously Treated Metastatic Adenocarcinoma of the Pancreas, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine followed by CRS-207 (Arm B).
Primary Outcome
OS will be measured from date of randomization until death or end of followup (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis).
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG CY
- BIOLOGICAL CRS-207
- BIOLOGICAL GVAX
Study Locations (5)
California
- University of California, San Francisco - San Francisco
- Stanford University - Stanford
Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
Oregon
- Providence Portland Medical Center - Portland
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2015-01-02 |
| Est. Completion | 2017-07-21 |
| Phase | Phase 2 |
What the finished NCT02243371 record still lists
NCT02243371 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).
The record links to 1 condition, with Previously Treated Metastatic Adenocarcinoma of the Pancreas appearing as the primary indexed condition, and to 4 interventions - of which nivolumab is the first listed.
NCT02243371 lists 5 locations in 4 states (California, Maryland, Oregon).
Frequently Asked Questions
What is clinical trial NCT02243371 about?
NCT02243371 is a clinical study titled "GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab". The primary objective of this study is to compare the overall survival (OS) of subjects with previously treated metastatic pancreatic cancer treated with cyclophosphamide (CY)/nivolumab/GVAX pancreas vaccine followed by nivolumab/CRS-207 (Arm A) to subjects treated with CY/GVAX pancreas vaccine foll...
What is the current status of trial NCT02243371?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2015-01-02. Estimated completion is 2017-07-21.
What conditions does trial NCT02243371 study?
This clinical trial studies the following conditions: Previously Treated Metastatic Adenocarcinoma of the Pancreas.
What interventions are being tested in trial NCT02243371?
The interventions under investigation include: nivolumab (DRUG), CY (DRUG), CRS-207 (BIOLOGICAL), GVAX (BIOLOGICAL).
Who is sponsoring clinical trial NCT02243371?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02243371 being conducted?
This trial has 5 study locations across California, Maryland, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02243371's enrollment target sits among peer trials
93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI